Search - tctmd.com

Displaying 1 - 20 of 36

Sort: Relevancy | Date

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

L.A. McKeown

April 03, 2025

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

News Conference News ACC 2025

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Michael O'Riordan

March 31, 2025

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Caitlin E. Cox

March 30, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

L.A. McKeown

April 06, 2024

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Shelley Wood

April 06, 2024

News Conference News ACC 2024

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

Michael O'Riordan

April 06, 2024

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

News Conference News ACC 2023

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

L.A. McKeown

March 14, 2023

News Conference News ACC 2023

Real-world Primary MR TEER Outcomes Carry a Reminder: Do Better

Shelley Wood

March 10, 2023

News Conference News ACC 2023

Wearable Device Helps HF Patients Avoid Coming Back to the Hospital: BMAD

Caitlin E. Cox

March 06, 2023

News Conference News ACC 2023

Too Many HF Patients Exiting Rural Hospitals Miss Out on Endorsed Therapies

Caitlin E. Cox

February 23, 2023

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

L.A. McKeown

April 07, 2022

Seasonal, but No Year-round, Protection With Flu Shots in HF: IVVE

News Conference News ACC 2022

Seasonal, but No Year-round Help for HF With Flu Shots: IVVE

Yael L. Maxwell

April 03, 2022

SODIUM-HF: No Impact of Dietary Salt Restriction on Death or Hospitalization

News Conference News ACC 2022

SODIUM-HF: No Impact of Tighter Dietary Salt Restriction on Death or Hospitalization

L.A. McKeown

April 02, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

News Conference News ACC 2021

RAFT-AF: No Benefit of AF Ablation for Heart Failure Patients

Todd Neale

May 17, 2021

Presentation ACC 2021

Effect of a Hospital and Post-discharge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction

Presenter: Adam DeVore

May 17, 2021

Advertisement

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

By 2 Years, Tricuspid TEER Reduces Hospitalizations for HF: TRILUMINATE

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

What’s Going to Be Hot at ACC 2025?

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Interatrial Shunt Falls Short in Sham-Controlled RELIEVE-HF

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF

Real-world Primary MR TEER Outcomes Carry a Reminder: Do Better

Wearable Device Helps HF Patients Avoid Coming Back to the Hospital: BMAD

Too Many HF Patients Exiting Rural Hospitals Miss Out on Endorsed Therapies

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

Seasonal, but No Year-round Help for HF With Flu Shots: IVVE

SODIUM-HF: No Impact of Tighter Dietary Salt Restriction on Death or Hospitalization

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

RAFT-AF: No Benefit of AF Ablation for Heart Failure Patients

Effect of a Hospital and Post-discharge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content